Caladrius Biosciences Inc reports results for the quarter ended in December - Earnings Summary

Lisata Therapeutics

22/03/2022 21:01

* Caladrius Biosciences Inc  CLBS.OQ  reported a quarterly
adjusted loss of 11 cents​​ per share for the quarter ended in
December. The mean expectation of two analysts for the quarter
was for a loss of 14 cents per share.
    * Reported revenue was zero​;  analysts expected zero. 
    * Caladrius Biosciences Inc's reported EPS for the quarter
was a
loss of 11 cents​.
    * The mean earnings estimate of analysts was unchanged in
the last
three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * Caladrius Biosciences Inc shares had fallen by 11.2% this
quarter.
    * The company reported a quarterly loss of $6.79 million.
    * Wall Street's median 12-month price target for Caladrius
Biosciences Inc is $9.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 

This summary was machine generated March 22 at 09:01 p.m.  ​All
figures in US dollars unless otherwise stated